Concurrent radiation with irinotecan and carboplatin in intermediate- and high-risk rhabdomyosarcoma: A report on toxicity and efficacy from a prospective pilot phase II study

Pediatric Blood and Cancer

Volumn 60, Issue 2, 2013, Pages 242-247

  Dharmarajan, Kavita V ^a   Wexler, Leonard H ^a   Wolden, Suzanne L ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

Author keywords

Carboplatin; Irinotecan; Phase II study; Radiation therapy; Rhabdomyosarcoma; Toxicity

Indexed keywords

CARBOPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; MESNA; VINCRISTINE;

ADOLESCENT; ADULT; ARTICLE; CANCER CONTROL; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER RISK; CHILD; COHORT ANALYSIS; CONTROLLED STUDY; CYSTITIS; DERMATITIS; DIARRHEA; DRUG EFFICACY; DRUG TOLERABILITY; DYSPHAGIA; ELECTRON THERAPY; ESOPHAGITIS; FATIGUE; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEMORRHAGIC CYSTITIS; HIGH RISK POPULATION; HUMAN; HUMAN TISSUE; INFANT; INTENSITY MODULATED RADIATION THERAPY; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA AND VOMITING; PHASE 2 CLINICAL TRIAL; PILOT STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; PROCTITIS; PROSPECTIVE STUDY; RADIATION DERMATITIS; RADIATION DOSE; RADIATION INDUCED EMESIS; RADIATION INJURY; RADIATION SICKNESS; RHABDOMYOSARCOMA; SCHOOL CHILD; TREATMENT OUTCOME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; CARBOPLATIN; CHEMORADIOTHERAPY; CHILD; FEMALE; HUMANS; MALE; PILOT PROJECTS; RHABDOMYOSARCOMA; SOFT TISSUE NEOPLASMS;

EID: 84871133745     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24205     Document Type: Article

References (25)

1. Raney RB, Maurer HM, Anderson JR, et al. The Intergroup Rhabdomyosarcoma Study Group (IRSG): Major lessons From the IRS-I through IRS-IV studies as background for the current IRS-V treatment protocols. Sarcoma 2001; 5: 9-15.
2. Pappo AS, Lyden E, Breneman J, et al. Up-front window trial of topotecan in previously untreated children and adolescents with metastatic rhabdomyosarcoma: An intergroup rhabdomyosarcoma study. J Clin Oncol 2001; 19: 213-219.
3. Walterhouse DO, Lyden ER, Breitfeld PP, et al. Efficacy of topotecan and cyclophosphamide given in a phase II window trial in children with newly diagnosed metastatic rhabdomyosarcoma: A Children's Oncology Group study. J Clin Oncol 2004; 22: 1398-1403.
4. Saylors RL III, Stine KC, Sullivan J, et al. Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A Pediatric Oncology Group phase II study. J Clin Oncol 2001; 19: 3463-3469.
5. Nitschke R, Parkhurst J, Sullivan J, et al. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study. J Pediatr Hematol Oncol 1998; 20: 315-318.
6. Houghton PJ, Cheshire PJ, Hallman JC, et al. Therapeutic efficacy of the topoisomerase I inhibitor 7-ethyl-10-(4-[1-piperidino]-1-piperidino)-carbonyloxy-camptothecin against human tumor xenografts: Lack of cross-resistance in vivo in tumors with acquired resistance to the topoisomerase I inhibitor 9-dimethylaminomethyl-10-hydroxycamptothecin. Cancer Res 1993; 53: 2823-2829.
7. Houghton PJ, Cheshire PJ, Hallman JD II, et al. Efficacy of topoisomerase I inhibitors, topotecan and irinotecan, administered at low dose levels in protracted schedules to mice bearing xenografts of human tumors. Cancer Chemother Pharmacol 1995; 36: 393-403.
8. Furman WL, Stewart CF, Poquette CA, et al. Direct translation of a protracted irinotecan schedule from a xenograft model to a phase I trial in children. J Clin Oncol 1999; 17: 1815-1824.
9. Blaney S, Berg SL, Pratt C, et al. A phase I study of irinotecan in pediatric patients: A pediatric oncology group study. Clin Cancer Res 2001; 7: 32-37.
10. Vassal G, Droz F, Frappaz D, et al. A Phase trial of irinotecan (CPT-11) in children. Proc Am Soc Clin Oncol 1999; 18: 563a.
11. Cosetti M, Wexler LH, Calleja E, et al. Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J Pediatr Hematol Oncol 2002; 24: 101-105.
12. Wexler LH. Data presented at the Connective Tissue Oncology Society, 2001 Annual Meeting. West Palm Beach, FL, 2001.
13. Takeda K, Negoro S, Kudoh S, et al. Phase I/II study of weekly irinotecan and concurrent radiation therapy for locally advanced non-small cell lung cancer. Br J Cancer 1999; 79: 1462-1467.
14. Choy H, Chakravarthy A, Devore RF III, et al. Weekly irinotecan and concurrent radiation therapy for stage III unresectable NSCLC. Oncology (Williston Park) 2000; 14: 43-46.
15. Knox JJ, Wong R, Visbal AL, et al. Phase 2 trial of preoperative irinotecan plus cisplatin and conformal radiotherapy, followed by surgery for esophageal cancer. Cancer 2010; 116: 4023-4032.
16. Michel P, Adenis A, Di Fiore F, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: Multicenter phase II FFCD trial. Br J Cancer 2006; 95: 705-709.
17. Chisholm JC, Machin D, McDowell H, et al. Efficacy of carboplatin given in a phase II window study to children and adolescents with newly diagnosed metastatic soft tissue sarcoma. Eur J Cancer 2007; 43: 2537-2544.
18. Frascella E, Pritchard-Jones K, Modak S, et al. Response of previously untreated metastatic rhabdomyosarcoma to combination chemotherapy with carboplatin, epirubicin and vincristine. Eur J Cancer 1996; 32A: 821-825.
19. Levy AS, Meyers PA, Wexler LH, et al. Phase 1 and pharmacokinetic study of concurrent carboplatin and irinotecan in subjects aged 1 to 21 years with refractory solid tumors. Cancer 2009; 115: 207-216.
20. National Cancer Institute (U.S.). Common terminology criteria for adverse events (CTCAE) (ed Rev.). Bethesda, MD: U. S. Department of Health and Human Services, National Institutes of Health, National Cancer Institute; 2003.
21. National Cancer Institute. Phase III randomized study of vincristine, dactinomycin, and cyclophosphamide (VAC) versus VAC alternating with vincristine and irinotecan hydrochloride in combination with radiotherapy in patients with newly diagnosed, intermediate-risk rhabdomyosarcoma. clinical trials (PDQ) homepage. http://www.cancer.gov/clinicaltrials/search/view?cdrid=487560&version=HealthProfessional. Published July 14, 2006. Accessed March 29, 2012.
22. Lin C, Donaldson SS, Meza JL, et al. Effect of radiotherapy techniques (IMRT vs. 3D-CRT) on outcome in patients with intermediate-risk rhabdomyosarcoma enrolled in COG D9803-A report from the Children's Oncology Group. Int J Radiat Oncol Biol Phys 2012; 82: 1764-1770.
23. La TH, Meyers PA, Wexler LH, et al. Radiation therapy for Ewing's sarcoma: Results from Memorial Sloan-Kettering in the modern era. Int J Radiat Oncol Biol Phys 2006; 64: 544-550.
24. Donaldson SS, Meza J, Breneman JC, et al. Results from the IRS-IV randomized trial of hyperfractionated radiotherapy in children with rhabdomyosarcoma-A report from the IRSG. Int J Radiat Oncol Biol Phys 2001; 51: 718-728.
25. Wolden SL, Wexler LH, Kraus DH, et al. Intensity-modulated radiotherapy for head-and-neck rhabdomyosarcoma. Int J Radiat Oncol Biol Phys 2005; 61: 1432-1438.